Oncology
Latest news
826 articles · 20 / page
Comprehensive Overview of the AMPLITUDE Trial Results on Niraparib and AAP in HRR-Deficient Prostate Cancer
The AMPLITUDE trial demonstrated that adding niraparib to abiraterone acetate plus prednisone significantly improves progression-free survival in HRR-deficient metastatic prostate cancer, with maintained quality of life and manageable safet
Genomically Matched Therapy Improves Response and PFS Across Advanced Solid Tumors: Phase 2 ROME Trial
The randomized phase 2 ROME trial showed that genomically matched, MTB-guided therapy increased overall response rate and progression-free survival versus standard care in heavily pretreated advanced solid tumors, supporting a tumor-agnosti
Neoadjuvant PD‑1/LAG‑3 Bispecific (tobemstomig) Matches Efficacy but Improves Safety Versus Nivolumab‑Ipilimumab in Resectable Stage III Melanoma: Insights from Morpheus‑Melanoma
The randomized phase 1b/2 Morpheus‑Melanoma trial found that tobemstomig (anti‑PD‑1/anti‑LAG‑3 bispecific) produced comparable pathological response rates to nivolumab plus ipilimumab with a substantially improved safety profile in resectab
Lazertinib Matches Osimertinib Efficacy in First-Line EGFR‑Mutant Advanced NSCLC: Exploratory Results from MARIPOSA
In the MARIPOSA randomized, double-blind exploratory analysis, lazertinib monotherapy showed comparable progression-free survival, response rates, overall survival (interim), and tolerability to osimertinib in treatment-naive EGFR‑mutant ad
Prolonged Survival Transforms Leptomeningeal Metastasis in NSCLC: Contemporary Multicenter Cohort Shows TKIs and ICIs Improve Outcomes
An international cohort of 2,052 NSCLC patients with leptomeningeal disease shows rising prevalence and improved survival in the modern treatment era. CNS‑penetrant tyrosine kinase inhibitors and immune checkpoint inhibitors are key drivers
Immune Checkpoint Inhibitors Amplify Risk and Delay Onset of SJS/TEN: Evidence for a Two‑Hit Mechanism
A large FAERS analysis links immune checkpoint inhibitors (ICIs) to markedly increased SJS/TEN risk, demonstrates additive synergy with high‑risk small molecules, and shows delayed latency particularly with anti–PD‑1 agents — supporting a t
Hormonal Contraceptive Progestin Content Strongly Modifies Breast Cancer Risk in Adolescents and Premenopausal Women
A Swedish nationwide cohort (n≈2.1M) found small but measurable variation in breast cancer risk by hormonal contraceptive formulation—higher with desogestrel/etonogestrel products and lower with levonorgestrel-containing devices; absolute e
Ezabenlimab plus mDCF Induction and Adaptive Chemoradiotherapy Achieve High Complete Response Rates in Stage 3 Squamous Cell Anal Carcinoma (INTERACT-ION)
The INTERACT-ION phase 2 trial reports that induction ezabenlimab with modified DCF followed by biomarker-guided, involved-node radiotherapy produced high clinical complete response rates (overall 77.8%) with a manageable safety profile in
Pirfenidone plus Steroids Improves Gas Transfer in Grade 2–3 Radiation‑Induced Lung Injury: Phase 2 Multicentre Randomised Trial
A multicentre phase 2 randomised trial found pirfenidone added to standard glucocorticoids improved DLCO% at 24 weeks versus steroids alone in grade 2–3 radiation‑induced lung injury, with manageable safety and no treatment‑related deaths.
Zanzalintinib Plus Atezolizumab Prolongs Survival Versus Regorafenib in Refractory MSS Colorectal Cancer: STELLAR-303 Phase 3 Results
The phase 3 STELLAR-303 trial shows zanzalintinib plus atezolizumab improves overall survival versus regorafenib in previously treated, microsatellite-stable metastatic colorectal cancer, albeit with higher grade ≥3 toxicity.
Global Gaps and Delays in Care for Breast, Cervical, and Ovarian Cancer: Insights from 275,792 Women in the VENUSCANCER Analysis
The VENUSCANCER secondary analysis of 275,792 records from 103 population-based registries reveals wide global variation in stage at diagnosis, concordance with guideline-recommended initial treatments, and time to treatment for breast, cer
Izalontamab Brengitecan Doubles Response Rates Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma
A phase 3 randomized trial in China showed the EGFR/HER3 bispecific antibody‑drug conjugate izalontamab brengitecan produced a 54.6% objective response rate versus 27.0% with chemotherapy in heavily pretreated recurrent or metastatic nasoph
Durvalumab Combined with BCG for High-Risk, BCG-Naive Non-Muscle-Invasive Bladder Cancer: Final Phase 3 Trial Results from POTOMAC Study
One year of durvalumab combined with BCG induction and maintenance significantly improved disease-free survival in patients with high-risk, BCG-naive non-muscle-invasive bladder cancer compared to BCG therapy alone, with a manageable safety
Breaking the Immortality of Cancer Cells: Israel’s Groundbreaking RNA-Targeting Drug
Israeli scientists have developed a novel small molecule drug that targets RNA structures maintaining cancer cell immortality, providing a promising new approach to treating hard-to-cure cancers with unparalleled precision.
SUPREMO Ten-Year Results: Chest‑Wall Irradiation After Mastectomy Lowers Local Recurrence but Does Not Improve 10‑Year Survival in Intermediate‑Risk Breast Cancer
The SUPREMO randomized trial found that postmastectomy chest‑wall irradiation reduces chest‑wall recurrence but does not improve 10‑year overall survival for intermediate‑risk breast cancer; a large real‑world analysis supports no overall s
What patients and clinicians want to know next: UK–Ireland research priorities for oesophageal and stomach cancers
A UK–Ireland partnership ranked the top research uncertainties for oesophagogastric cancers; priorities emphasize personalising multimodal treatment, nutrition and quality of life, and stronger patient-centred trial design to accelerate mea
ENDURO trial: EUS‑guided gastroenterostomy shortens time to oral intake and matches surgery for palliation of malignant gastric outlet obstruction
A randomized trial (ENDURO) found endoscopic ultrasound‑guided gastroenterostomy (EUS‑GE) enabled earlier resumption of solid food and was non‑inferior to surgical gastrojejunostomy for recurrent obstruction, supporting EUS‑GE as preferred
CTNNA1 Truncating Variants Define a Moderate-Penetrance Hereditary Diffuse Gastric Cancer Spectrum — Implications for Testing, Surveillance and Risk Reduction
Large clinical and functional study shows CTNNA1-truncating variants cause loss of αE-catenin via nonsense-mediated decay, confer substantially elevated risks of diffuse gastric cancer and lobular breast cancer versus general population but
Multi‑armoured oncolytic HSV‑1 (VG161) shows immune remodelling and promising activity in advanced intrahepatic cholangiocarcinoma: pooled early‑phase insights
Pooled Phase I/IIa data (n=24) indicate intratumoural VG161 is well tolerated in advanced intrahepatic cholangiocarcinoma, elicits local and systemic immune activation (APC recruitment, CD8+ T‑cell activation, M2 macrophage depletion) and s
PDE5A-Positive Cancer-Associated Fibroblasts Drive Immune Exclusion in Gastric Cancer — Therapeutic Rationale for Combining PDE5 Inhibition with LAG3 Blockade
Single‑cell and spatial profiling identify a PDE5A+ CAF subset that remodels stroma, activates PI3K/AKT/mTOR–CXCL12 signaling, and recruits exhausted LAG3+ CD8 T cells, promoting immune exclusion in gastric cancer. Vardenafil plus LAG3 bloc
Browse by specialty
Open language-specific specialty feeds and department pages.